Aurobindo Pharma Reports Q2 Revenue of 102.63B Rupees Versus 82.85B YoY

Market snapshot: Aurobindo Pharma Limited announced its consolidated Q2 FY27 financial results, generating record quarterly revenue from operations of ₹10,263 crore compared to ₹8,286 crore in Q2 FY26. Net profit for the quarter rose to ₹1,124 crore, driven by robust performance across US and European markets.

Data Snapshot

• Aurobindo Pharma reported consolidated revenue from operations of ₹10,263 crore in Q2 FY27, representing a 23.9% YoY increase over ₹8,286 crore recorded in Q2 FY26.
• Consolidated net profit reached ₹1,124 crore in Q2 FY27, up 32.5% YoY compared to ₹848 crore in Q2 FY26.
• EBITDA before forex and other income stood at ₹2,156 crore for Q2 FY27, up 28.5% YoY, expanding EBITDA margin by 75 bps YoY to 21.0%.

What's Changed

• Revenue from operations expanded to ₹10,263 crore in Q2 FY27 from ₹8,286 crore in Q2 FY26.
• Net profit increased to ₹1,124 crore in Q2 FY27 from ₹848 crore in Q2 FY26.

Key Takeaways

• Aurobindo Pharma delivered its highest-ever quarterly revenue from operations of ₹10,263 crore in Q2 FY27.
• US formulations revenue surged 25% YoY to ₹4,555 crore ($477 million).
• Europe formulations revenue grew 27% YoY to ₹3,161 crore (€288 million).
• Growth Markets revenue rose 16% YoY to ₹1,026 crore ($107 million).

SAHI Perspective

Aurobindo Pharma's Q2 FY27 operational results reflect strong organic volume growth and market share expansion across major export destinations. Broad-based double-digit top-line growth in both the US and Europe coupled with a 75 bps expansion in EBITDA margin to 21.0% demonstrates operating leverage and strategic execution across key therapeutic segments.

Market Implications

The double-digit top-line and profit expansion reinforces earnings visibility for Aurobindo Pharma. Continued growth in high-margin formulation markets supports cash flow generation and balance sheet strength, positioning the company favorably relative to broader pharmaceutical peers.

Trading Signals

Market Bias: Bullish

Aurobindo Pharma achieved record quarterly revenue of ₹10,263 crore (up 23.9% YoY) and net profit growth of 32.5% YoY to ₹1,124 crore in Q2 FY27, underpinned by 25% YoY expansion in US formulation sales and margin improvement to 21.0%.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Sustained formulation revenue expansion in North America and Europe
• Execution of product launches and USFDA regulatory approvals
• Maintenance of EBITDA margins above 20%

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian pharmaceutical export sector continues to see demand recovery across North America and Europe, supported by stable pricing dynamics in generic formulations and key product launches.

Key Risks to Watch

• Regulatory oversight and inspection outcomes from global health authorities including USFDA
• Foreign currency exchange rate volatility impacting international revenues
• Raw material cost fluctuations affecting core formulations margins

Recent Developments

No verified developments in this window

Closing Insight

Sustained execution across formulation markets and margin expansion provide a firm foundation for Aurobindo Pharma's operational performance.

High Performance Trading with SAHI.